Post-treatment renal function deterioration following radiation therapy: implications for SABR in primary renal cell cancer - Summary - MDSpire

Post-treatment renal function deterioration following radiation therapy: implications for SABR in primary renal cell cancer

  • By

  • Marthe Sophie Kilian

  • Laura Anna Fischer

  • Jona Bensberg

  • Lisa-Antonia von Diest

  • Carla Marie Zwerenz

  • Mahalia Z. Anczykowski

  • Stephanie Bendrich

  • Manuel Guhlich

  • Martin Leu

  • Leif Hendrik Dröge

  • Tibor I. Kesztyüs

  • Annemarie Uhlig

  • Stefan Rieken

  • Rami A. El Shafie

  • June 23, 2026

  • 0 min

Share

Objective:

To evaluate post-treatment renal results and dose-response following kidney irradiation to guide nephron-sparing SABR for primary renal cell carcinoma (pRCC).

Approach:
    Key Findings:
    • 46.98% of patients experienced deterioration of CKD during a median follow-up of 170 days (IQR 60-541).
    • Increased renal dose was an independent predictor of decline in renal function (HR 1.04/Gy; p=0.028 for mean; p=0.014 for max).
    • Female gender was identified as a risk factor for renal function decline (HR 2.08; p<0.001).
    • Established thresholds for mean and max kidney doses were 18.7 Gy and 19.0 Gy, respectively.
    Interpretation:

    Radiation exposure in low-to-moderate dose ranges targeting non-tumorous renal tissue was linked to a dose-dependent reduction in renal function post-treatment.

    Limitations:
    • The retrospective nature of the study restricts causal interpretation and may introduce bias.
    • Further validation is necessary due to limitations in the study design.
    Conclusion:

    Nephron-sparing SABR represents a secure therapeutic approach for pRCC.

Original Source(s)

Post-treatment renal function deterioration following radiation therapy: implications for SABR in primary renal cell cancer

  • by Marthe Sophie Kilian, Laura Anna Fischer, Jona Bensberg, Lisa-Antonia von Diest, Carla Marie Zwerenz, Mahalia Z. Anczykowski, Stephanie Bendrich, Manuel Guhlich, Martin Leu, Leif Hendrik Dröge, Tibor I. Kesztyüs, Annemarie Uhlig, Stefan Rieken, Rami A. El Shafie

  • June 23, 2026

Related Content

C5orf46: a promising prognosis risk indicator with implication in the remodeling of KIRC and pan-cancer tumor microenvironments

Multi-omics analysis of kidney renal cell carcinoma in silico with preliminary in vivo validation

Obesity-driven metabolic reprogramming and immune dysfunction in renal cancer